Connect with us

Global Affairs

Angelina Jolie criticises governments over inaction on wartime sexual violence | Ending sexual violence in conflict

Angelina Jolie has decried the lack of action by governments to support survivors of wartime rape as “deeply painful and frustrating”.

The actor and UN special envoy for refugees, who launched the Preventing Sexual Violence in Conflict Initiative (PSVI) with the then foreign secretary William Hague in 2012, said there had not been “nearly enough” progress on bringing perpetrators to justice, prioritising survivors’ needs or ending impunity.

Writing in the Guardian today, she said: “There has been some progress … but it has not been nearly enough to meet the needs of survivors, or to deter perpetrators from using rape as a weapon of war in almost every new conflict in the past decade.

“Despite the commitments governments made, we have not seen significant, lasting action at the global level. This is deeply painful and frustrating.”

As the British government marks the 10th anniversary of PSVI with a conference in London, Jolie said: “We meet and discuss these horrors and agree that they should never be allowed to happen again. We promise to draw – and to hold – that line.

“But when it comes to hard choices about how to implement these promises, we run into the same problems time and again. We run into some security council members abusing their veto power, such as in the case of Syria. We run into economic and political interests being put first, treating some conflicts as more important than others. And we run into a lack of political will, meaning that governments in recent years have downgraded the importance of efforts to combat war-zone sexual violence, despite the direct link to international peace and security.”

Ministers and representatives from 70 countries are expected to attend the two-day PSVI summit, which begins on Monday. They will be joined by survivors of violence and Nobel laureates Nadia Murad and Denis Mukwege.

Tariq Ahmad, the UK prime minister’s special representative for PSVI, said the conference will “drive new action”, secure new commitments (including funding) and “discuss how to strengthen the global response to these crimes and how to address some of the real root causes, including gender discrimination”.

The UK government announced on Monday £12.5m of new funding over three years to tackle violence. Most of the money will be used to support survivors.

The foreign secretary, James Cleverly, said: “The very threat of rape and sexual violence as a weapon of war should bring immediate international condemnation and swift action to stop those attacks before they start.

“So today, we stand in solidarity to support survivors and to bring justice. But also to send an unequivocal message to those who order, allow or perpetrate sexual violence: we will not tolerate it and we will push for perpetrators to be prosecuted.”

But Nimco Ali, the chief executive of the Five Foundation, an organisation working for women and girls around the world, said pledging money was not enough.

“It is not enough that we see renewed commitments,” she said. “It has been proven they are not sufficient or reliable. The Foreign, Commonwealth and Development Office needs to embed change at its core and update its own systemic priorities by putting the principles of gender equality at the heart of its aid and diplomacy policies.”

Ali added that money must be given to local women’s organisations. “Unless international aid and foreign diplomacy strategies include unshakeable and specific financial commitments for women and girls at grassroots level – in countries where the specific instances of violence are happening – we will be back here again in 10 years’ time,” she said.

Eva Tabbasam, the director of Gender Action for Peace and Security, said £12.5m was “a drop in the ocean compared to the amount of money that has been cut from gender equality programming”.

Last year saw a £3bn reduction in the overseas aid budget, with further cuts estimated in the next few years. An analysis of UK aid between 2019 and 2022 showed the cuts had a significant detrimental impact on women and girls’ lives.

Yasmin Sooka, the chair of the UN commission on human rights in South Sudan, said the war in Ukraine meant that the organisations that survivors of sexual violence depend on in South Sudan and other countries had seen their funds cut in recent years.

“The international community needs to stop these violations in South Sudan, but in the absence of peace at least we should be able to patch up the victims,” she said.

A PSVI summit held in London in 2014 – attended by 1,700 politicians, celebrities, and survivors – was criticised for costing more than five times the 2015 UK budget for tackling rape in war zones.

In 2020, a damning report by the aid watchdog said PSVI had “not fully delivered on its ambitions and is at risk of letting survivors down”.

Source link

Current

Congratulations, Privacy Just Took A Great Leap Out the Window!

Your Data Is Being Used Without Your Permission And Knowledge

The Voice Of EU | In the heart of technological innovation, the collision between intellectual property rights and the development of cutting-edge AI technologies has sparked a significant legal battle. The New York Times has taken legal action against OpenAI and Microsoft, filing a lawsuit in Manhattan federal court. This legal maneuver aims to address concerns surrounding the unauthorized use of the Times’ content for the training of AI models, alleging copyright infringements that could potentially result in billions of dollars in damages.

READ: HOW YOUR DATA IS BEING USED TO TRAIN A.I.

This legal tussle underlines the escalating tension between technological advancements and the protection of intellectual property. The crux of the lawsuit revolves around OpenAI and Microsoft allegedly utilizing the Times’ proprietary content to advance their own AI technology, directly competing with the publication’s services. The lawsuit suggests that this unauthorized utilization threatens the Times’ ability to offer its distinctive service and impacts its AI innovation, creating a competitive landscape that challenges the publication’s proprietary content.

Amidst the growing digital landscape, media organizations like the Times are confronting a myriad of challenges. The migration of readers to online platforms has significantly impacted traditional media, and the advent of artificial intelligence technology has added another layer of complexity. The legal dispute brings to the forefront the contentious practice of AI companies scraping copyrighted information from online sources, including articles from media organizations, to train their generative AI chatbots. This strategy has attracted substantial investments, rapidly transforming the AI landscape.

Exhibit presented by the New York Times’ legal team of ChatGPT replicating a article after being prompted

The lawsuit highlights instances where OpenAI’s technology, specifically GPT-4, replicated significant portions of Times articles, including in-depth investigative reports. These outputs, alleged by the Times to contain verbatim excerpts from their content, raise concerns about the ethical and legal boundaries of using copyrighted material for AI model training without proper authorization or compensation.

The legal action taken by the Times follows attempts to engage in discussions with Microsoft and OpenAI, aiming to address concerns about the use of its intellectual property. Despite these efforts, negotiations failed to reach a resolution that would ensure fair compensation for the use of the Times’ content while promoting responsible AI development that benefits society.

In the midst of this legal battle, the broader questions surrounding the responsible and ethical utilization of copyrighted material in advancing technological innovations come to the forefront.

The dispute between the Times, OpenAI, and Microsoft serves as a significant case study in navigating the intricate intersection of technological progress and safeguarding intellectual property rights in the digital age.


Continue Reading

Culture

Conflicted History: ‘Oppenheimer’ And Its Impact On Los Alamos And New Mexico Downwinders

‘Oppenheimer’ And Its Impact On Los Alamos And New Mexico Downwinders

The Voice Of EU | In the highly anticipated blockbuster movie, “Oppenheimer,” the life of J. Robert Oppenheimer, the man behind the first atomic bomb, is portrayed as a riveting tale of triumph and tragedy.

As the film takes center stage, it also brings to light the often-overlooked impacts on a community living downwind from the top-secret Manhattan Project testing site in southern New Mexico.

A Forgotten Legacy

While the film industry and critics praise “Oppenheimer,” a sense of frustration prevails among the residents of New Mexico’s Tularosa Basin, who continue to grapple with the consequences of the Manhattan Project. Tina Cordova, a cancer survivor and founder of the Tularosa Basin Downwinders Consortium, expresses their feelings, stating, “They invaded our lives and our lands and then they left,” referring to the scientists and military personnel who conducted secret experiments over 200 miles away from their community.

The Consortium, alongside organizations like the Union of Concerned Scientists, has been striving to raise awareness about the impact of the Manhattan Project on New Mexico’s population. Advocates emphasize the necessity of acknowledging the human cost of the Trinity Test, the first atomic blast, and other nuclear weapons activities that have affected countless lives in the state.

The Ongoing Struggle for Recognition

As film enthusiasts celebrate the drama and brilliance of “Oppenheimer,” New Mexico downwinders feel overlooked by both the U.S. government and movie producers. The federal government’s compensation program for radiation exposure still does not include these affected individuals. The government’s selection of the remote and flat Trinity Test Site, without warning residents in the surrounding areas, further added to the controversy.

Living off the land, the rural population in the Tularosa Basin had no idea that the fine ash settling on their homes and fields was a result of the world’s first atomic explosion.

The government initially attempted to cover up the incident, attributing the bright light and rumble to an explosion at a munitions dump. It was only after the U.S. dropped atomic bombs on Japan weeks later that New Mexico residents realized the magnitude of what they had witnessed.

Tracing the Fallout

According to the Manhattan Project National Historical Park, large amounts of radiation were released into the atmosphere during the Trinity Test, with fallout descending over a vast area. Some of the fallout reached as far as the Atlantic Ocean, but the greatest concentration settled approximately 30 miles from the test site.

Now I Am Become Death, the Destroyer of Worlds.

J. Robert Oppenheimer

The consequences of this catastrophic event have affected generations of New Mexicans, who still await recognition and justice for the harm caused by nuclear weapons.

A Tale of Contrasts: Los Alamos and the Legacy of Oppenheimer

As the film’s spotlight shines on the life of J. Robert Oppenheimer, a contrasting narrative unfolds in Los Alamos, more than 200 miles north of the Tularosa Basin. Los Alamos stands as a symbol of Oppenheimer’s legacy, housing one of the nation’s premier national laboratories and boasting the highest percentage of people with doctorate degrees in the U.S.

Oppenheimer’s influence is evident throughout Los Alamos, with a street bearing his name and an IPA named in his honor at a local brewery. The city embraces its scientific legacy, showcasing his handwritten notes and ID card in a museum exhibit. Los Alamos National Laboratory employees played a significant role in the film, contributing as extras and engaging in enlightening discussions during breaks.

The “Oppenheimer” Movie

Director Christopher Nolan’s perspective on the Trinity Test and its profound impact is evident in his approach to “Oppenheimer.” He has described the event as an extraordinary moment in human history and expressed his desire to immerse the audience in the pivotal moment when the button was pushed. Nolan’s dedication to bringing historical accuracy and emotional depth to the screen is evident as he draws inspiration from Kai Bird and Martin J. Sherwin’s Pulitzer Prize-winning book, “American Prometheus: The Triumph and Tragedy of J. Robert Oppenheimer.

For Nolan, Oppenheimer’s story is a potent blend of dreams and nightmares, capturing the complexity and consequences of the Manhattan Project. As the film reaches global audiences, it also offers a unique opportunity to raise awareness about the downwinders in New Mexico, whose lives were forever altered by the legacy of nuclear weapons testing.

The Oppenheimer Festival and Beyond

Los Alamos is determined to use the Oppenheimer Festival as an opportunity to educate visitors about the true stories behind the film’s events. The county’s “Project Oppenheimer” initiative, launched in early 2023, encompasses forums, documentaries, art installations, and exhibits that delve into the scientific contributions of the laboratory and the social implications of the Manhattan Project.

A special area during the festival will facilitate discussions about the movie, fostering a deeper understanding of the community’s history. The county aims to continue revisiting and discussing the legacy of the Manhattan Project, ensuring that the impact of this pivotal moment in history is never forgotten.

As “Oppenheimer” takes audiences on an emotional journey, it serves as a reminder that every historical event carries with it complex and multifaceted implications. The movie may celebrate the scientific achievements of the past, but it also illuminates the urgent need to recognize and address the human cost that persists to this day.


We Can’t Thank You Enough For Your Support!

— By Team VoiceOfEU.com

— For Info.: info@VoiceOfEU.com

— Anonymous Submissions: press@VoiceOfEU.com


Continue Reading

Current

GSK’s Mosquirix Is Revolutionizing The Fight Against Malaria

GSK’s Mosquirix And The Fight Against Malaria

Over the past three years, the global focus has primarily been on the Covid-19 pandemic, diverting attention and resources away from other infectious diseases that disproportionately affect vulnerable populations in the Global South. Among these diseases, malaria continues to be a pressing public health concern, claiming the lives of hundreds of thousands of people each year, especially children in Sub-Saharan Africa. While significant progress has been made in preventing and treating malaria, innovative solutions are needed to combat this deadly disease.

Advancements in Malaria Prevention:

Researchers have made remarkable progress in both prevention and treatment strategies for malaria. The World Health Organization’s recommendation of dual-ingredient insecticide-treated bed nets in March 2023 marks a significant milestone in preventing malaria transmission by Anopheles mosquitoes. These nets, including those with more lethal insecticide combinations and those disrupting mosquito growth, are key tools in malaria prevention efforts.

LEARN MORE: ALL ABOUT HEALTHCARE

The Importance of Cost-Effective Antimalarial Medicines:

Cost-effective antimalarial medicines play a crucial role in combating malaria. In 2021, approximately 45 million children between the ages of three months and five years received seasonal malaria chemoprevention, which involved monthly doses of therapeutic drugs at a cost of less than $4 per person. While this approach has shown promising results, the development of a groundbreaking vaccine brings renewed hope.

GSK’s Mosquirix (RTS,S) Vaccine:

GSK’s Mosquirix, also known as RTS,S, is an innovative vaccine that has the potential to transform the fight against malaria. This vaccine offers hope in preventing the disease, particularly among children in malaria-endemic regions. Although the current cost is relatively high, around $40 per child for the first year, it presents an essential step forward in malaria prevention efforts.

The Persistent Threat of Malaria:

Despite substantial investments of $26 billion to combat malaria in Sub-Saharan Africa, the number of cases has seen a slight increase between 2000 and 2019, although the number of deaths has decreased. This highlights the need for new prevention measures tailored to vulnerable populations, especially children. Taking inspiration from the Covid-19 pandemic, where monoclonal antibodies have demonstrated their potential, similar approaches could be explored in the fight against malaria.

The Potential of Monoclonal Antibodies:

Monoclonal antibodies, laboratory-made copies of immune system proteins, have shown immense potential in combating various diseases, including cancer and autoimmune disorders. Their remarkable selectivity and ability to target specific molecular markers make them an attractive option for preventive interventions. Researchers at the United States National Institutes of Health, led by Robert Seder, have identified two antibodies that target CSP-1, a protein used by the malaria parasite to invade liver cells. Clinical trials are currently underway in Mali and Kenya to assess their safety and efficacy, focusing on seasonal and year-round malaria transmission settings.

Game-Changing Potential:

Monoclonal antibodies have the potential to be a game-changer in malaria prevention, advancing the long-sought goal of eradication. The latest generation of antimalarial antibodies offers extended protection, with a single dose potentially safeguarding a child for at least three months, if not longer. Clinical trials will determine the extent and duration of this protection and guide future improvements to achieve a once-a-year injection.

Making Monoclonal Antibodies Accessible:

While monoclonal antibodies are often associated with high costs, efforts to increase their potency could significantly reduce expenses. It is estimated that an injection as small as one milliliter of the antibody drug being trialed in Mali and Kenya could protect children at a cost of only $5-10 per person. To ensure accessibility, it is crucial to engage national regulatory agencies and involve affected countries in the production of these biologics. While manufacturing antibodies is a complex and regulated process, investing in the necessary technology now would greatly benefit developing economies burdened by endemic malaria.

Addressing Disparities and Raising Awareness:

Currently, demand for monoclonal antibodies primarily comes from high-income countries, with Africa accounting for only 1% of global sales. This disparity underscores the importance of working with national regulatory agencies to address public health concerns and involve affected countries in the production and distribution of these life-saving biologics. Collaboration among government, academia, and industry is crucial to coordinate advocacy efforts and raise awareness about the potential of monoclonal antibodies in malaria prevention.

Preparing for Success:

While the deployment of the first generation of antimalarial antibodies is expected to occur no earlier than 2027, it is essential to start preparing for their potential success now. These antibodies hold tremendous promise as a powerful weapon in the fight against malaria, alongside bed nets, medicines, and emerging vaccines. Clinical trials will provide vital information on the extent of their efficacy, duration of protection, and dosage requirements. It is imperative to remain proactive and ensure that the necessary infrastructure and policies are in place to facilitate the widespread adoption of these breakthrough treatments.

Combining Science & Research:

As the world continues to battle the ongoing Covid-19 pandemic, it is crucial not to overlook the persistent threat of malaria, especially in regions heavily impacted by poverty. While significant progress has been made in malaria prevention and treatment, the development of innovative solutions like GSK’s Mosquirix vaccine and the potential of monoclonal antibodies offer renewed hope in the fight against this deadly disease. By harnessing the lessons learned from Covid-19 research and engaging in collaborative efforts, we can work towards a future where malaria is no longer a major public health concern. Together, we can strive for the eradication of malaria and ensure a healthier future for vulnerable populations worldwide.


By Laura Richardson | Independent Contributor “The Voice Of EU

Thank You For Your Support!

— Compiled by Team VoiceOfEU.com

— For More: info@VoiceOfEU.com

— Anonymous News Submissions: press@VoiceOfEU.com


Continue Reading

Trending

Subscribe To Our Newsletter

Join our mailing list to receive the latest news and updates 
directly on your inbox.

You have Successfully Subscribed!